Fiscal Year: October - September
Hologic, Inc. (HOLX), listed on the NASDAQ, has a market capitalization of $. As of Nov 20, 2025, the stock is trading at $74.17 per share, offering investors a clear view of its current market value. Hologic, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 29.79, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Hologic, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Hologic, Inc. (HOLX) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Hologic, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Hologic, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Hologic, Inc. is 17.96, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Hologic, Inc. (HOLX) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Hologic, Inc. (HOLX) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Hologic, Inc. (HOLX) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Hologic, Inc.. To access the full SS Score, consider upgrading your subscription.
Hologic, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 29.79. Investors should compare these metrics with industry peers to gauge whether Hologic, Inc. is outperforming or underperforming within its sector.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #cemark--Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Holog...
Under the terms of the deal, Blackstone and TPG agreed to acquire all outstanding shares of the women's-health company for $76 apiece in cash.
Blackstone and TPG have agreed to acquire medical diagnostics firm Hologic in an up to $18.3 billion deal, the company said on Tuesday.
MARLBOROUGH, Mass. & NEW YORK & SAN FRANCISCO & FORT WORTH, Texas--(BUSINESS WIRE)---- $HOLX #aquisition--Hologic to be Acquired by Blackstone and TPG for up to $79 per Share.
The maker of women's health products rejected a $16 billion offer from the parties in May.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #Bacterial--Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fus...
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #BCAM--New Survey Results Underscore the Need to #BustTheMyth About Mammograms.
HENDERSON, Nev. , Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Holog...
HAUPPAUGE, N.Y. , Sept. 29, 2025 /PRNewswire/ -- Minicarm.com, a leading provider of imaging solutions for orthopedic and surgical practices, is proud to announce that it has secured an allocation of ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI.
Private equity firms Blackstone and TPG revived their interest in acquiring medical device maker Hologic , a person close to the transaction said on Wednesday.
Hologic, Inc. (NASDAQ:HOLX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Stephen MacMillan - Chairman, CEO & President Conference Call P...
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference.
Hologic, Inc. (NASDAQ:HOLX) Q3 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Essex D. Mitchell - Chief Operating Officer Karleen M.
Medical equipment maker Hologic on Wednesday raised its annual profit forecast, anticipating strong demand for its molecular diagnostic devices and surgical products.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Third Quarter of Fiscal 2025.
I am initiating a Buy rating on Hologic, Inc. with a fair value of $81, as current risks are priced in. Hologic's strong diagnostic portfolio, recurring consumables revenue, and expanding assay menu s...
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025.
ARLINGTON, Va.--(BUSINESS WIRE)--NEST, an initiative of MDIC, is pleased to welcome Hologic, a leading global medical device company, to its Governance Committee.
Private equity firms TPG and Blackstone BX recently bid to acquire Hologic Inc. HOLX, valuing the U.S. medical technology company at over $16 billion.
Medical equipment maker Hologic rejected a $16 billion non-binding offer from private equity firms TPG and Blackstone , the Financial Times reported on Tuesday, citing people familiar with the matter.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #ASCO--Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 1.05B | Analyst x2 | |
| 2027 | 1.09B | 4.10% | Analyst x2 |
| 2028 | 1.16B | 6.46% | Analyst x2 |
| 2029 | 1.20B | 3.67% | Est @3.7% |
| 2030 | 1.24B | 3.14% | Est @3.1% |
| 2031 | 1.28B | 2.93% | Est @2.9% |
| 2032 | 1.31B | 2.79% | Est @2.8% |
| 2033 | 1.35B | 2.69% | Est @2.7% |
| 2034 | 1.38B | 2.44% | Est @2.4% |
| 2035 | 1.42B | 2.39% | Est @2.4% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 1.16B | 1.00 | 1.16B |
| 2025A | 920.10M | 1.00 | 920.10M |
| 2026E | 1.05B | 1.08 | 966.49M |
| 2027E | 1.09B | 1.18 | 927.88M |
| 2028E | 1.16B | 1.27 | 911.01M |
| 2029E | 1.20B | 1.38 | 871.00M |
| 2030E | 1.24B | 1.50 | 828.50M |
| 2031E | 1.28B | 1.63 | 786.46M |
| 2032E | 1.31B | 1.76 | 745.53M |
| 2033E | 1.35B | 1.91 | 706.00M |
| 2034E | 1.38B | 2.07 | 666.95M |
| 2035E | 1.42B | 2.25 | 629.80M |
| Terminal | 24.45B | 2.25 | 10.88B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.
